NSAIDS and selective COX-2 inhibitors: competition between gastroprotection and cardioprotection
- 1 April 2001
- journal article
- Published by Elsevier in The Lancet
- Vol. 357 (9264) , 1222-1223
- https://doi.org/10.1016/s0140-6736(00)04451-2
Abstract
No abstract availableThis publication has 12 references indexed in Scilit:
- Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid ArthritisNew England Journal of Medicine, 2000
- Gastrointestinal Toxicity With Celecoxib vs Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis and Rheumatoid ArthritisJAMA, 2000
- Epidemiology of cardiovascular disease in systemic lupus erythematosusLupus, 2000
- COX-2 inhibitorsThe Lancet, 1999
- Risk of major gastrointestinal bleeding with aspirinThe Lancet, 1999
- Aspirin: benefit and risk in thromboprophylaxisQJM: An International Journal of Medicine, 1998
- Omeprazole Compared with Misoprostol for Ulcers Associated with Nonsteroidal Antiinflammatory DrugsNew England Journal of Medicine, 1998
- Is aspirin safe for patients with heart failure?Heart, 1995
- Misoprostol Reduces Serious Gastrointestinal Complications in Patients with Rheumatoid Arthritis Receiving Nonsteroidal Anti-Inflammatory DrugsAnnals of Internal Medicine, 1995
- Cardiovascular Mortality in Patients with Rheumatoid ArthritisCardiology, 1989